Medicine for relieving severe asthma, application and animal model construction method

Abstract

The invention belongs to the technical field of severe asthma action mechanisms, and discloses a medicine for relieving severe asthma, application and an animal model construction method, the medicine is an HDAC10 inhibitor, and the action mechanism of HDAC10 for regulating and controlling Th17 / IL-17A expression in severe asthma is clarified by using the construction method; the interaction mode of HDAC10 and STAT3 is defined; it is proved that HDAC10 deacetylated STAT3 regulates and controls the expression of Th17 / IL-17A in severe asthma. it is determined that the HDAC10 inhibitor can relieve severe asthma, and an experimental basis is provided for HDAC10 targeted therapy of severe asthma. it is determined that the HDAC10 inhibitor can relieve severe asthma, and an experimental basis is provided for HDAC10 targeted therapy of severe asthma. Compared with a control group, the intraperitoneal injection of the HDAC10 inhibitor can improve airway inflammation, airway hyperreactivity and airway mucus secretion of a severe asthma mouse model mainly comprising neutrophile granulocytes.

Description

Technical field [0001] The present invention belongs to the technical field of severe asthma, and more particularly to drugs, applications and animal model constructs for alleviating severe asthma. Background technique [0002] There are currently 300 million asthma patients around the world, and there are about 3 million asthma patients in my country, is one of the highest asthma. Therefore, studying asthma occurring and developing new molecular mechanisms, looking for new asthma treatment is still an urgent task of asthma researchers. Clinical studies have found more than 40% of asthma based on neutral granulocyte inflammation. At the same time, about 10% to 15% severe asthma patients are not sensitive to even large doses of glucocorticoid inhalation, or have a certain degree of resistance [2]. Most of these patients are severe asthma, and their fertile features are different from mild asthma, while similar to slow resistance. The traditional TH2 type immune response cannot exp...

AI Technical Summary

Problems solved by technology

[0004] (1) The pathogenesis of neutrophil-dominated severe asthma has not been clarified

[0005] (2) The specific mechanism of action of Th17 / IL-17 in severe asthma is not yet clear

[0006] (3) It is not yet clear whether epigenetic modification can regulate Th17 / IL-17 and improve the symptoms of severe asthma

[0010] Previous research on the molecular mechanism of asthma mainly focused on the eosinophilic airway inflammatory response mediated by the Th2 immune response. In view of the hormone resistance in severe asthma dominated by neutrophils, clinical treatment is difficult

Images